ISB News

ISB K-12 Science Education Team Helps ‘STEM’ School Develop Curriculum

Riverpoint Academy in Spokane has been working with ISB’s K-12 science education team to develop curriculum that falls under “STEM” – science, technology, engineering and math. Riverpoint describes itself as a STEM school that also teaches arts, humanities and entrepreneurship. Some educators and administrators from Riverpoint and the Mead School District, as well as other community leaders visited ISB on May 3 and 4 to participate in a workshop to discuss how a signature project could be developed around personalized health. On May 21, students from Riverpoint Academy attended a panel featuring ISB scientists and then took a tour of the high-tech facilities. In April, Dr. Lee Hood, ISB president, traveled to Spokane to visit with students in the Mead District, including at Riverpoint Academy. Read the Spokesman Review’s story about the visit.

Recent Articles

  • Dr. Sean Gibbons Promoted to Associate Professor

    Dr. Sean Gibbons – an expert in microbial ecology and evolution, computational systems biology, the human gut microbiome and its impacts on health, and head of ISB’s Gibbons Lab – has been promoted to Associate Professor. “Sean’s achievements since joining ISB in 2018 as a Washington Research Foundation Distinguished Investigator have been spectacular,” ISB President Dr. Jim Heath said. “With his focus on the microbiome, he brought a whole new…

  • AmeriCorps Member Sara Calder Joins ISB as Systems Health and STEM Coordinator

    Sara Calder recently joined ISB as Systems Health and STEM Coordinator, and is our second-ever AmeriCorps member. In this Q&A, Calder shares her education journey, her future plans, and much more.

  • In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer

    Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.